Cathie Wood’s ARK ETFs made a series of trades on Tuesday, April 9, 2024, as part of regular portfolio adjustments. The transactions involved both purchases and sales in various sectors, with particular attention to technology and healthcare.
The biggest transaction of the day was the sale of 51,316 shares of UiPath Inc (NYSE:), a company specializing in robotic process automation. This sale was split between the ARKG and ARKX ETFs, for a total dollar value of $1,110,991. This move comes after an earlier sell-off of UiPath shares last Wednesday, indicating a trend in ARK’s investment strategy.
Another significant sale was that of 9,973 shares of Incyte Corp (NASDAQ:), a biopharmaceutical company, through the ARKG ETF, in the amount of $549,013. This sale may reflect ARK’s shift in focus to the biotech sector.
On the buy side, ARK has invested heavily Iridium communications Inc (NASDAQ:), purchasing a total of 34,438 shares of the ARKQ and ARKX ETFs, for a total value of $875,413. This investment highlights ARK’s interest in satellite communications technologies.
Additionally, ARK purchased 68,122 shares of Teladoc Inc (NYSE:NYSE:), a telemedicine company, across four different ETFs (ARKK, ARKW, ARKG, and ARKF), for a total of $995,943. This purchase confirms ARK’s bullish position in the telemedicine sector.
Other notable purchases included 12,647 shares of Year Inc (NASDAQ:) and 52,700 shares of Recursion Pharmaceuticals (NASDAQ:RXRX), with a total dollar value of $769,569 and $474,300, respectively. These deals are part of ARK’s ongoing investments in streaming technology and pharmaceuticals.
Smaller operations included buying shares of companies such as Archer Aviation Inc (NYSE:NYSE:), Crispr Therapeutics AG (NASDAQ:), Intellia Therapeutics Inc (NASDAQ:), Palantir Technologies Inc (NYSE:NYSE:), Staff Inc (NASDAQ:) and 10X Genomics Inc (NASDAQ:TXG).
These daily trades offer investors detailed information on ARK’s latest investment moves and the strategic adjustments they are making to their ETF portfolios. Investors and market watchers will likely continue to monitor ARK’s activity for indications of broader market trends and shifts in investment focus.
This article was generated with the support of AI and reviewed by an editor. For further information please see our T&Cs.